ArticlePharmaceutical statistics
Unblinded by the Night: Predictive Power for Complex Bayesian Adaptive Trials When Sight Privileges Vary.
Article in Pharmaceutical statistics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Well-controlled clinical trials employ careful processes to reduce bias, often blinding investigators and sponsors to prevent knowledge of study outcomes and potential operational bias. Quality assurance of outcomes is also ensured through designation of unblinded data managers and statisticians, so that complex adaptive designs with multiple interim analyses can be executed. Our approach addresses potential ad-hoc requests by the Data and Safety Monitoring Board (DSMB) for monitoring safety, efficacy, and ethical oversight. A novel approach utilizing current trial data is proposed to predict trial outcomes for blinded decision-makers without unblinding those that should stay blinded. Bayesian predictive power, a trial prediction method, is employed and illustrated on simulated data. This study presents an approach for presenting updated Bayesian predictive power in complex adaptive designs, exemplified by the Hyperbaric Oxygen Brain Injury Treatment (HOBIT) trial. Simulation examples motivated from the trial demonstrate the utility of Bayesian predictive power in predicting trial outcomes and sample size distribution, aiding in resource allocation and decision-making with different reports for blinded and unblinded teams. Bayesian predictive power calculations offer valuable insights into future trial behavior for both blinded and unblinded groups, aiding in guidance during trial conduction. The approach outlined in this short communication can be applied to various trial designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.